GLP-1 weight loss drugs face sustainability and muscle loss concerns

GLP-1 agonists, such as Ozempic, have transformed the approach to obesity treatment by mimicking hormones that slow stomach emptying and suppress appetite. While highly effective for weight loss, experts highlight significant limitations regarding long-term sustainability and physical health.

Research indicates that a substantial portion of weight lost through these medications—estimated between one-quarter and one-third—can consist of muscle tissue rather than fat. This loss of muscle mass can lead to a lower resting metabolism, reduced physical fitness, and an increased risk of injury. Furthermore, without accompanying changes to diet and physical activity, weight often returns quickly once the medication is discontinued.

Medical experts, including David A. Kessler, emphasize that obesity is often driven by biological factors rather than a lack of willpower. While these drugs are powerful tools, experts suggest that combining medical intervention with lifestyle changes, such as regular exercise and balanced nutrition, is essential for maintaining muscle mass and achieving lasting health outcomes.